Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05060276
Other study ID # T2ADC-RRST-101
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date December 2022
Est. completion date December 2024

Study information

Verified date January 2023
Source Sorrento Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.


Description:

This is a Phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors including ovarian, breast, lung, esophageal, gastric, hepatocellular and urothelial cancers. The study will determine any dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), assessing safety and preliminary efficacy using ascending dose cohorts and a conventional 3+3 study design.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed advanced cancer that is relapsing or refractory to at least one prior treatment and not a candidate for other treatments or is intolerant to established treatments. - At least one measurable disease per Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1). - Eastern Cooperative Oncology Group Performance Status = 2. - Must have a life expectancy of = 6 months. - Must have adequate bone marrow, hepatic and renal function as assessed by specific laboratory tests. - Must be recovered = Grade 1 from acute toxicities from previous therapies, excluding alopecia and vitiligo. - Has not had prior treatment within 2 weeks of screening with high dose corticosteroids. - Be willing and able to comply with the study schedule and all study requirements. - Willing to follow all contraception guidelines. Exclusion Criteria: - Previous treatment with any systemic therapy or investigational drug within 2 weeks of the first dose of study drug. - Currently participating in any other interventional clinical study. - Has a diagnosis of other malignancies if the malignancy has required therapy within the last 3 years or is not in complete remission. - Has presence of bulky disease defined as any mass > 7 cm in greatest dimension will trigger a discussion with the medical monitor. - Has left ventricular ejection fraction (LVEF) < 40%. - New York Heart Association (NYHA) Class = 3. - Has prolonged QTcF interval on an electrocardiogram. - Has spinal cord compression or clinically active brain metastases. - Has a history of Sacituzumab govitecan treatment. - History of anaphylactic reaction to irinotecan or = Grade 3 toxicity to prior irinotecan treatment. - Has active or prior COVID-19 infection, with symptoms presenting within 4 weeks of the first dose of study drug. - Has an active bacterial, viral, or fungal infection. - Is currently pregnant or breast feeding or planning on either during the study. - Has chronic or moderate chronic obstructive pulmonary disease or other chronic respiratory conditions unless receiving treatment and stable for 3 months prior to screening. - Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C. - Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation.

Study Design


Intervention

Biological:
STI-3258
Intravenous infusion of STI-3258 will be given (one infusion every three weeks).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sorrento Therapeutics, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events by type, frequency, severity, and causality (safety) Safety as assessed by incidence of adverse events (AEs) by type, frequency, severity, and causality Baseline through study completion at up to approximately 24 months
Primary Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety) Safety as assessed by incidence of treatment-emergent AEs (TEAEs) by type, frequency, severity, and causality Baseline through study completion at up to approximately 24 months
Primary Incidence of serious adverse events by type, frequency, severity, and causality (safety) Safety as assessed by incidence of serious AEs (SAEs) by type, frequency, severity, and causality Baseline through study completion at up to approximately 24 months
Primary Incidence of Infusion-related adverse events by type, frequency, severity, and causality (safety) Safety as assessed by incidence of Infusion-related AEs (IrAEs) by type, frequency, severity, and causality Baseline through study completion at up to approximately 24 months
Primary Incidence of dose-limiting toxicities (safety) Safety as assessed by incidence of dose-limiting toxicities Baseline through study completion at up to approximately 24 months
Primary Determine the MTD Determine the MTD of STI-3258 Baseline through study completion at up to approximately 24 months
Primary Determine the RP2D To determine the RP2D of STI-3258 Baseline through study completion at up to approximately 24 months
Secondary Assess preliminary efficacy of STI-3258 To assess the preliminary efficacy of STI-3258 in the treatment of patients with RRSTs based upon Response evaluation criteria in solid tumors (RECIST). Baseline through study completion at up to approximately 24 months
Secondary Assess the area under the curve (AUC) pharmacokinetic profile of STI-3258 To assess the AUC of STI-3258 in plasma as a measure of exposure to the ADC, STI-3258. Baseline through study completion at up to approximately 24 months
See also
  Status Clinical Trial Phase
Terminated NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Active, not recruiting NCT05054348 - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Enrolling by invitation NCT06088004 - A Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors Phase 1
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Completed NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Withdrawn NCT05071846 - MVX-ONCO-2 in Advanced Solid Tumors Phase 1
Recruiting NCT05607199 - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics Phase 1
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Active, not recruiting NCT06026254 - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial Phase 1
Recruiting NCT06144671 - GT201 Injection For The Treatment Of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06032845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11) Phase 2
Recruiting NCT05276284 - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Phase 1/Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Recruiting NCT05435339 - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting NCT06075849 - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent Phase 1
Recruiting NCT04092673 - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Phase 1/Phase 2